[Gln22]-beta-Amyloid (1-40), Dutch Mutation – 0.5 mg

Overview

Discover our premium [Gln22]-beta-Amyloid (1-40), Dutch Mutation peptide, specifically formulated for research related to Alzheimer’s disease. This peptide is pivotal in studying the mechanisms behind early onset familial Alzheimer’s, as the Dutch mutation replaces Glu 22 with Gln, resulting in the accelerated formation of neurotoxic aggregates. These aggregates are notable for their increased resistance to proteolysis, making them a critical focus in neurodegenerative research.

Key Features

• Effectively promotes beta-Amyloid aggregation
• Essential for studying familial Alzheimer’s disease
• High purity for reliable results
• Available in a convenient 0.5 mg format
• Supports a wide range of research applications

Specifications

FAQ

What is the significance of the Dutch mutation of beta-Amyloid?

The Dutch mutation in beta-Amyloid plays a crucial role in understanding familial Alzheimer’s disease. It leads to rapid accumulation of neurotoxic aggregates, which are important for studying disease pathology.

How can I use [Gln22]-beta-Amyloid in my research?

This peptide can be utilized in various applications, including studies on protein aggregation, neurotoxicity assays, and drug development to combat Alzheimer’s disease. You can also explore our PKG substrates for enhanced assays.

What are the storage conditions for this peptide?

Store the peptide at -20°C to maintain its integrity and effectiveness. Ensure that it remains protected from light and moisture. For optimal results, it is recommended to aliquot and avoid repeated freeze-thaw cycles.

This peptide is an indispensable tool for any laboratory focused on Alzheimer’s research. Integrate it into your studies for a deeper understanding of beta-Amyloid’s role in neurodegeneration. To complement your research, check out our range of peptides and other relevant products.

Related Products

• Autocamtide-2 [KKALRRQETVDAL]
• CREBtide [KRREILSRRPSYR], 5-FAM labeled